211 related articles for article (PubMed ID: 28566016)
1. A computational study to identify the key residues of peroxisome proliferator-activated receptor gamma in the interactions with its antagonists.
Sharifi T; Ghayeb Y
J Biomol Struct Dyn; 2018 May; 36(7):1822-1833. PubMed ID: 28566016
[TBL] [Abstract][Full Text] [Related]
2. Agonism activities of lyso-phosphatidylcholines (LPC) Ligands binding to peroxisome proliferator-activated receptor gamma (PPARγ).
Wang J; Wang B; Zhang Y
J Biomol Struct Dyn; 2020 Feb; 38(2):398-409. PubMed ID: 31025599
[TBL] [Abstract][Full Text] [Related]
3. Structural and Dynamical Insight into PPARγ Antagonism: In Silico Study of the Ligand-Receptor Interactions of Non-Covalent Antagonists.
Fratev F; Tsakovska I; Al Sharif M; Mihaylova E; Pajeva I
Int J Mol Sci; 2015 Jul; 16(7):15405-24. PubMed ID: 26184155
[TBL] [Abstract][Full Text] [Related]
4. Computational investigation of phytochemicals from
Omoboyowa DA; Singh G; Fatoki JO; Oyeneyin OE
J Biomol Struct Dyn; 2023; 41(12):5568-5582. PubMed ID: 35773777
[TBL] [Abstract][Full Text] [Related]
5. Probing the intermolecular interactions of PPARγ-LBD with polyunsaturated fatty acids and their anti-inflammatory metabolites to infer most potential binding moieties.
Muralikumar S; Vetrivel U; Narayanasamy A; N Das U
Lipids Health Dis; 2017 Jan; 16(1):17. PubMed ID: 28109294
[TBL] [Abstract][Full Text] [Related]
6. Identification of dual ligands targeting angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ by core hopping of telmisartan.
Zhang J; Liu X; Wang SQ; Liu GY; Xu WR; Cheng XC; Wang RL
J Biomol Struct Dyn; 2017 Sep; 35(12):2665-2680. PubMed ID: 27602589
[TBL] [Abstract][Full Text] [Related]
7. CHARMM Force Field Parameterization of Peroxisome Proliferator-Activated Receptor γ Ligands.
Mottin M; Souza PC; Ricci CG; Skaf MS
Int J Mol Sci; 2016 Dec; 18(1):. PubMed ID: 28025495
[TBL] [Abstract][Full Text] [Related]
8. Homology modeling and molecular docking studies on Type II diabetes complications reduced PPARγ receptor with various ligand molecules.
Prabhu S; Vijayakumar S; Manogar P; Maniam GP; Govindan N
Biomed Pharmacother; 2017 Aug; 92():528-535. PubMed ID: 28575810
[TBL] [Abstract][Full Text] [Related]
9. Scaffold-based pan-agonist design for the PPARα, PPARβ and PPARγ receptors.
Zhang LS; Wang SQ; Xu WR; Wang RL; Wang JF
PLoS One; 2012; 7(10):e48453. PubMed ID: 23119024
[TBL] [Abstract][Full Text] [Related]
10. PPARγ non-covalent antagonists exhibit mutable binding modes with a similar free energy of binding: a case study.
Fratev F
J Biomol Struct Dyn; 2017 Feb; 35(3):476-485. PubMed ID: 26872742
[TBL] [Abstract][Full Text] [Related]
11. Study of new interactions of glitazone's stereoisomers and the endogenous ligand 15d-PGJ2 on six different PPAR gamma proteins.
Álvarez-Almazán S; Bello M; Tamay-Cach F; Martínez-Archundia M; Alemán-González-Duhart D; Correa-Basurto J; Mendieta-Wejebe JE
Biochem Pharmacol; 2017 Oct; 142():168-193. PubMed ID: 28716729
[TBL] [Abstract][Full Text] [Related]
12. Identification of novel PPARα/γ dual agonists by virtual screening, ADMET prediction and molecular dynamics simulations.
Liu X; Jing Z; Jia WQ; Wang SQ; Ma Y; Xu WR; Liu JW; Cheng XC
J Biomol Struct Dyn; 2018 Aug; 36(11):2988-3002. PubMed ID: 28853334
[TBL] [Abstract][Full Text] [Related]
13. Structure based docking and molecular dynamics studies: Peroxisome proliferator-activated receptors -α/γ dual agonists for treatment of metabolic disorders.
Nath V; Agrawal R; Kumar V
J Biomol Struct Dyn; 2020 Feb; 38(2):511-523. PubMed ID: 30767625
[TBL] [Abstract][Full Text] [Related]
14. Multi-conformation dynamic pharmacophore modeling of the peroxisome proliferator-activated receptor γ for the discovery of novel agonists.
Sohn YS; Park C; Lee Y; Kim S; Thangapandian S; Kim Y; Kim HH; Suh JK; Lee KW
J Mol Graph Model; 2013 Nov; 46():1-9. PubMed ID: 24104184
[TBL] [Abstract][Full Text] [Related]
15. Combined biophysical and cell-based approaches for the assessment of ligand binding to PPARγ.
Zorrilla S; Pérez-Sala D
Methods Mol Biol; 2013; 952():237-52. PubMed ID: 23100238
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, activity, and docking study of phenylthiazole acids as potential agonists of PPARγ.
Ma L; Wang T; Shi M; Ye H
Drug Des Devel Ther; 2016; 10():1807-15. PubMed ID: 27313447
[TBL] [Abstract][Full Text] [Related]
17. Structure-based identification of novel PPAR gamma ligands.
da Silva FM; dos Santos JC; Campos JL; Mafud AC; Polikarpov I; Figueira AC; Nascimento AS
Bioorg Med Chem Lett; 2013 Nov; 23(21):5795-802. PubMed ID: 24075729
[TBL] [Abstract][Full Text] [Related]
18. X-ray crystal structure of rivoglitazone bound to PPARγ and PPAR subtype selectivity of TZDs.
Rajapaksha H; Bhatia H; Wegener K; Petrovsky N; Bruning JB
Biochim Biophys Acta Gen Subj; 2017 Aug; 1861(8):1981-1991. PubMed ID: 28499821
[TBL] [Abstract][Full Text] [Related]
19. Different binding and recognition modes of GL479, a dual agonist of Peroxisome Proliferator-Activated Receptor α/γ.
dos Santos JC; Bernardes A; Giampietro L; Ammazzalorso A; De Filippis B; Amoroso R; Polikarpov I
J Struct Biol; 2015 Sep; 191(3):332-40. PubMed ID: 26185032
[TBL] [Abstract][Full Text] [Related]
20. Exploring Dual Agonists for PPARα/γ Receptors using Pharmacophore Modeling, Docking Analysis and Molecule Dynamics Simulation.
Ding TT; Liu YY; Zhang LM; Shi JR; Xu WR; Li SY; Cheng XC
Comb Chem High Throughput Screen; 2022; 25(9):1450-1461. PubMed ID: 34182904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
